Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To evaluate the current French screening guidelines for retinopathy of prematurity (ROP) and to suggest modifications to it.
Methods: In this multicentric retrospective, noncomparative, interventional case series we included infants with a gestational age (GA) ≤32 weeks who were screened for ROP by fundus examination between 2011 and 2018. Main Outcome Measures were the presence of ROP and the need for treatment.
Results: A total of 2246 children with a mean GA of 28.9 ± 2.0 weeks and mean birth weight (BW) of 1141.1 ± 332.0 g were screened. Retinopathy of prematurity (ROP) was found in 683 infants (30.4%), of whom 145 (6.5%) had type 2 ROP and 58 (2.6%) had type 1 ROP. Mean GA of infants with type 1 ROP needing treatment was 25.9 + 1.5 weeks (range: 23.6-30) and mean BW was 774.1 ± 173.7 g (range: 540-1400). Both GA and BW had an impact on the development of type 1 and 2 ROP. None of the infants needing treatment had a GA of 31 weeks or more. None of the children needed treatment before 33 weeks of postmenstrual age (PMA) or 6 weeks of postnatal age (PNA).
Conclusion: It seems possible to decrease the screening of premature infants to ≤31 weeks of GA and to start screening at 31 weeks PMA for infants having a GA < 26 weeks and at 6 weeks PNA for more mature children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/aos.15091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Review of Retinopathy of Prematurity Management in the Anti-VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI-Assisted Future.
Clin Exp Ophthalmol
September 2025
Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
Retinopathy of prematurity (ROP) remains a major cause of preventable blindness in premature infants worldwide, with increasing incidence due to advancements in neonatal care. Management of ROP has been revolutionised by anti-vascular endothelial growth factor (anti-VEGF) treatments. Pivotal clinical trials have demonstrated the efficacy of anti-VEGF in the management of Type 1 ROP, while investigation of safety and long-term effects is ongoing.
View Article and Find Full Text PDFReactivation of retinopathy of prematurity after anti-VEGF treatment: a review.
Br J Ophthalmol
August 2025
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, Delhi, India
Anti-vascular endothelial growth factor (anti-VEGF) agents have demonstrated efficacy and short-term safety in the treatment of retinopathy of prematurity (ROP), establishing them as the preferred option for zone I and zone II posterior disease. Despite their advantages, the effects of anti-VEGF agents are relatively temporary. Consequently, ROP may reactivate or recur if retinal vascularisation has not sufficiently progressed and significant areas of avascular anterior retina remain while the anti-VEGF agents are cleared from the vitreous cavity.
View Article and Find Full Text PDFFrom Screening to Therapy: A Personalized Approach to ROP in a National NICU Setting.
J Pers Med
August 2025
Ophthalmology Department Makarios Hospital, Nicosia 2011, Cyprus.
: We aimed to investigate the incidence, treatment patterns, and associated risk factors of type 1 retinopathy of prematurity (ROP) in the only tertiary-level Neonatal Intensive Care Unit (NICU) in Cyprus. : This retrospective study included all infants screened for ROP between January and December 2023. Data were collected from standardized NICU discharge summaries and included gestational age (GA), birth weight (BW), multiple birth, systemic infection, blood transfusion, oxygen therapy, surgical interventions, and ROP outcomes.
View Article and Find Full Text PDFEffect of Ranibizumab in Patients with Treatment-Naïve Retinopathy of Prematurity.
Turk J Ophthalmol
August 2025
Post-Graduate Medical Institute/Lahore General Hospital, Clinic of Pediatric, Lahore, Pakistan.
Objectives: To determine the effect of intravitreal ranibizumab (IVR) in patients with treatment-naïve retinopathy of prematurity (ROP) in terms of disease regression and need for rescue therapy.
Materials And Methods: This study evaluated disease regression and rescue therapy requirement in treatment-naïve ROP cases treated with IVR. Among 188 screened patients, 80 had ROP.
A twin-paired study on the independent effect of birth weight on retinopathy of prematurity.
Int Ophthalmol
August 2025
Department of Ophthalmology, Faculty of Medicine, Ordu University, Ordu, Turkey.
Purpose: To evaluate the effect of discrepancy between birth weight (BW) of twin preterm babies on retinopathy of prematurity (ROP) development.
Methods: Medical records of twins who were followed up for ROP between 2014 and 2023 were reviewed retrospectively. A total number of 254 twin babies with a gestational age (GA) of ≤ 34 weeks were included in the study.